Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1080 entries
Sorted by: Best Match Show Resources per page
TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.

Blood advances

Haribhai D, Luo X, Chen J, Jia S, Shi L, Schroeder JA, Weiler H, Aster RH, Hessner MJ, Hu J, Williams CB, Shi Q.
PMID: 28164173
Blood Adv. 2016 Dec 13;1(2):139-151. doi: 10.1182/bloodadvances.2016001453.

Platelets are a rich source of many cytokines and chemokines including transforming growth factor β 1 (TGF-β1). TGF-β1 is required to convert conventional CD4

Cite
Haribhai D, Luo X, Chen J, et al. TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood Adv. 2016;1(2):139-151doi: 10.1182/bloodadvances.2016001453.
Haribhai, D., Luo, X., Chen, J., Jia, S., Shi, L., Schroeder, J. A., Weiler, H., Aster, R. H., Hessner, M. J., Hu, J., Williams, C. B., & Shi, Q. (2016). TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood advances, 1(2), 139-151. https://doi.org/10.1182/bloodadvances.2016001453
Haribhai, Dipica, et al. "TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice." Blood advances vol. 1,2 (2016): 139-151. doi: https://doi.org/10.1182/bloodadvances.2016001453
Haribhai D, Luo X, Chen J, Jia S, Shi L, Schroeder JA, Weiler H, Aster RH, Hessner MJ, Hu J, Williams CB, Shi Q. TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood Adv. 2016 Dec 13;1(2):139-151. doi: 10.1182/bloodadvances.2016001453. PMID: 28164173; PMCID: PMC5288643.
Copy Download .nbib Format: NLM
Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015.

Blood advances

Dinmohamed AG, Issa DE, van der Poel MWM, Schouten HC, Lugtenburg PJ, Chamuleau MED, Zweegman S, Visser O.
PMID: 29297513
Blood Adv. 2017 Sep 22;1(21):1839-1841. doi: 10.1182/bloodadvances.2017011031. eCollection 2017 Sep 26.

No abstract available.

Cite
Dinmohamed AG, Issa DE, van der Poel MWM, et al. Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015. Blood Adv. 2017;1(21):1839-1841doi: 10.1182/bloodadvances.2017011031.
Dinmohamed, A. G., Issa, D. E., van der Poel, M. W. M., Schouten, H. C., Lugtenburg, P. J., Chamuleau, M. E. D., Zweegman, S., & Visser, O. (2017). Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015. Blood advances, 1(21), 1839-1841. https://doi.org/10.1182/bloodadvances.2017011031
Dinmohamed, Avinash G, et al. "Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015." Blood advances vol. 1,21 (2017): 1839-1841. doi: https://doi.org/10.1182/bloodadvances.2017011031
Dinmohamed AG, Issa DE, van der Poel MWM, Schouten HC, Lugtenburg PJ, Chamuleau MED, Zweegman S, Visser O. Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015. Blood Adv. 2017 Sep 22;1(21):1839-1841. doi: 10.1182/bloodadvances.2017011031. eCollection 2017 Sep 26. PMID: 29297513; PMCID: PMC5728101.
Copy Download .nbib Format: NLM
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.

Blood advances

Morgan EA, Sweeney MP, Tomoka T, Kopp N, Gusenleitner D, Redd RA, Carey CD, Masamba L, Kamiza S, Pinkus GS, Neuberg DS, Rodig SJ, Milner DA, Weinstock DM.
PMID: 29296697
Blood Adv. 2016 Nov 22;1(1):84-92. doi: 10.1182/bloodadvances.2016000026. eCollection 2016 Nov 29.

Diagnostics and supportive care for patients with non-Hodgkin lymphoma (NHL) in lower- and middle-income countries (LMICs) are lacking. We hypothesized that high-throughput transcription-based diagnostics could classify NHL specimens from Malawi amenable to targeted therapeutics. We established tissue microarrays and...

Cite
Morgan EA, Sweeney MP, Tomoka T, et al. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Adv. 2016;1(1):84-92doi: 10.1182/bloodadvances.2016000026.
Morgan, E. A., Sweeney, M. P., Tomoka, T., Kopp, N., Gusenleitner, D., Redd, R. A., Carey, C. D., Masamba, L., Kamiza, S., Pinkus, G. S., Neuberg, D. S., Rodig, S. J., Milner, D. A., & Weinstock, D. M. (2016). Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood advances, 1(1), 84-92. https://doi.org/10.1182/bloodadvances.2016000026
Morgan, Elizabeth A, et al. "Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities." Blood advances vol. 1,1 (2016): 84-92. doi: https://doi.org/10.1182/bloodadvances.2016000026
Morgan EA, Sweeney MP, Tomoka T, Kopp N, Gusenleitner D, Redd RA, Carey CD, Masamba L, Kamiza S, Pinkus GS, Neuberg DS, Rodig SJ, Milner DA, Weinstock DM. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Adv. 2016 Nov 22;1(1):84-92. doi: 10.1182/bloodadvances.2016000026. eCollection 2016 Nov 29. PMID: 29296697; PMCID: PMC5744047.
Copy Download .nbib Format: NLM
Direct evidence for a polygenic etiology in familial multiple myeloma.

Blood advances

Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Cibulskis C, Weinhold N, Försti A, Alici E, Langer C, Pfreundschuh M, Goldschmidt H, Mellqvist UH, Turesson I, Waage A, Hemminki K, Golub T, Nahi H, Gullberg U, Hansson M, Nilsson B.
PMID: 29296704
Blood Adv. 2017 Apr 07;1(10):619-623. doi: 10.1182/bloodadvances.2016003111. eCollection 2017 Apr 11.

Although common risk alleles for multiple myeloma (MM) were recently identified, their contribution to familial MM is unknown. Analyzing 38 familial cases identified primarily by linking Swedish nationwide registries, we demonstrate an enrichment of common MM risk alleles in...

Cite
Halvarsson BM, Wihlborg AK, Ali M, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017;1(10):619-623doi: 10.1182/bloodadvances.2016003111.
Halvarsson, B. M., Wihlborg, A. K., Ali, M., Lemonakis, K., Johnsson, E., Niroula, A., Cibulskis, C., Weinhold, N., Försti, A., Alici, E., Langer, C., Pfreundschuh, M., Goldschmidt, H., Mellqvist, U. H., Turesson, I., Waage, A., Hemminki, K., Golub, T., Nahi, H., Gullberg, U., Hansson, M., & Nilsson, B. (2017). Direct evidence for a polygenic etiology in familial multiple myeloma. Blood advances, 1(10), 619-623. https://doi.org/10.1182/bloodadvances.2016003111
Halvarsson, Britt-Marie, et al. "Direct evidence for a polygenic etiology in familial multiple myeloma." Blood advances vol. 1,10 (2017): 619-623. doi: https://doi.org/10.1182/bloodadvances.2016003111
Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Cibulskis C, Weinhold N, Försti A, Alici E, Langer C, Pfreundschuh M, Goldschmidt H, Mellqvist UH, Turesson I, Waage A, Hemminki K, Golub T, Nahi H, Gullberg U, Hansson M, Nilsson B. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017 Apr 07;1(10):619-623. doi: 10.1182/bloodadvances.2016003111. eCollection 2017 Apr 11. PMID: 29296704; PMCID: PMC5728350.
Copy Download .nbib Format: NLM
Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients.

Blood advances

Machado CM, Pereira BBS, Felix AC, Oliveira MC, Darrigo LG, de Souza MP, Paton EJA, Neves F, Colturato VR, Simoes BP.
PMID: 29296705
Blood Adv. 2017 Apr 10;1(10):624-627. doi: 10.1182/bloodadvances.2016003285. eCollection 2017 Apr 11.

No abstract available.

Cite
Machado CM, Pereira BBS, Felix AC, et al. Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients. Blood Adv. 2017;1(10):624-627doi: 10.1182/bloodadvances.2016003285.
Machado, C. M., Pereira, B. B. S., Felix, A. C., Oliveira, M. C., Darrigo, L. G., de Souza, M. P., Paton, E. J. A., Neves, F., Colturato, V. R., & Simoes, B. P. (2017). Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients. Blood advances, 1(10), 624-627. https://doi.org/10.1182/bloodadvances.2016003285
Machado, Clarisse Martins, et al. "Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients." Blood advances vol. 1,10 (2017): 624-627. doi: https://doi.org/10.1182/bloodadvances.2016003285
Machado CM, Pereira BBS, Felix AC, Oliveira MC, Darrigo LG, de Souza MP, Paton EJA, Neves F, Colturato VR, Simoes BP. Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients. Blood Adv. 2017 Apr 10;1(10):624-627. doi: 10.1182/bloodadvances.2016003285. eCollection 2017 Apr 11. PMID: 29296705; PMCID: PMC5728351.
Copy Download .nbib Format: NLM
Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.

Blood advances

Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marçais A, Marino-Merlo F, Turpin J, Bangham CR, Hermine O, Mastino A, Bazarbachi A.
PMID: 29296718
Blood Adv. 2017 May 05;1(12):748-752. doi: 10.1182/bloodadvances.2016001370. eCollection 2017 May 09.

The therapeutic efficacy of the AZT and IFN combination in ATL presumably reflects the inhibition of RT-related functions.HTLV-1-RT activity from short-term cultured PBMCs may represent a predictive correlate of clinical response to AZT/IFN in ATL patients.

Cite
Macchi B, Balestrieri E, Frezza C, et al. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. Blood Adv. 2017;1(12):748-752doi: 10.1182/bloodadvances.2016001370.
Macchi, B., Balestrieri, E., Frezza, C., Grelli, S., Valletta, E., Marçais, A., Marino-Merlo, F., Turpin, J., Bangham, C. R., Hermine, O., Mastino, A., & Bazarbachi, A. (2017). Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. Blood advances, 1(12), 748-752. https://doi.org/10.1182/bloodadvances.2016001370
Macchi, Beatrice, et al. "Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α." Blood advances vol. 1,12 (2017): 748-752. doi: https://doi.org/10.1182/bloodadvances.2016001370
Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marçais A, Marino-Merlo F, Turpin J, Bangham CR, Hermine O, Mastino A, Bazarbachi A. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. Blood Adv. 2017 May 05;1(12):748-752. doi: 10.1182/bloodadvances.2016001370. eCollection 2017 May 09. PMID: 29296718; PMCID: PMC5728049.
Copy Download .nbib Format: NLM
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis.

Blood advances

Caron F, Leong DP, Hillis C, Fraser G, Siegal D.
PMID: 29296721
Blood Adv. 2017 May 09;1(12):772-778. doi: 10.1182/bloodadvances.2016001883. eCollection 2017 May 09.

Ibrutinib therapy was associated with an increased risk of bleeding in previous trials. In this systematic review and meta-analysis of published trials including patients treated with ibrutinib, the relative risk (95% confidence interval [CI]) of overall bleeding was significantly...

Cite
Caron F, Leong DP, Hillis C, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772-778doi: 10.1182/bloodadvances.2016001883.
Caron, F., Leong, D. P., Hillis, C., Fraser, G., & Siegal, D. (2017). Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood advances, 1(12), 772-778. https://doi.org/10.1182/bloodadvances.2016001883
Caron, François, et al. "Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis." Blood advances vol. 1,12 (2017): 772-778. doi: https://doi.org/10.1182/bloodadvances.2016001883
Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017 May 09;1(12):772-778. doi: 10.1182/bloodadvances.2016001883. eCollection 2017 May 09. PMID: 29296721; PMCID: PMC5728050.
Copy Download .nbib Format: NLM
ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia.

Blood advances

Faulkner L, Uderzo C, Khalid S, Marwah P, Soni R, Yaqub N, Amanat S, Fatima I, Gilani SK, Zahra T, Ramprakash S, Gooneratne L, Dissanayake R, Williams S, Rathnayake W, Srinivas R, Sedai A, Kumari A, Parmar L, Dhanya R, Agarwal RK.
PMID: 29296723
Blood Adv. 2017 May 11;1(13):792-801. doi: 10.1182/bloodadvances.2016004119. eCollection 2017 May 23.

Matched-related bone marrow transplantation (BMT) may cure >80% of low-risk children with severe thalassemia (ST). Very long-term follow-up studies have shown how the standard busulfan-cyclophosphamide (BuCy) regimen may be associated with normalization of health-related quality of life, no second...

Cite
Faulkner L, Uderzo C, Khalid S, et al. ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017;1(13):792-801doi: 10.1182/bloodadvances.2016004119.
Faulkner, L., Uderzo, C., Khalid, S., Marwah, P., Soni, R., Yaqub, N., Amanat, S., Fatima, I., Gilani, S. K., Zahra, T., Ramprakash, S., Gooneratne, L., Dissanayake, R., Williams, S., Rathnayake, W., Srinivas, R., Sedai, A., Kumari, A., Parmar, L., Dhanya, R., & Agarwal, R. K. (2017). ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood advances, 1(13), 792-801. https://doi.org/10.1182/bloodadvances.2016004119
Faulkner, Lawrence, et al. "ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia." Blood advances vol. 1,13 (2017): 792-801. doi: https://doi.org/10.1182/bloodadvances.2016004119
Faulkner L, Uderzo C, Khalid S, Marwah P, Soni R, Yaqub N, Amanat S, Fatima I, Gilani SK, Zahra T, Ramprakash S, Gooneratne L, Dissanayake R, Williams S, Rathnayake W, Srinivas R, Sedai A, Kumari A, Parmar L, Dhanya R, Agarwal RK. ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017 May 11;1(13):792-801. doi: 10.1182/bloodadvances.2016004119. eCollection 2017 May 23. PMID: 29296723; PMCID: PMC5727808.
Copy Download .nbib Format: NLM
Therapy-related myelofibrosis does not appear to exist.

Blood advances

Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S.
PMID: 29296729
Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13.

There is no evidence to support the existence of therapy-related myelofibrosis.Therapy for previous malignancy has no impact on myelofibrosis prognosis.

Cite
Masarova L, Todisco G, Manshouri T, et al. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017;1(14):863-866doi: 10.1182/bloodadvances.2017007369.
Masarova, L., Todisco, G., Manshouri, T., Newberry, K. J., Cortes, J. E., Kantarjian, H. M., Estrov, Z., & Verstovsek, S. (2017). Therapy-related myelofibrosis does not appear to exist. Blood advances, 1(14), 863-866. https://doi.org/10.1182/bloodadvances.2017007369
Masarova, Lucia, et al. "Therapy-related myelofibrosis does not appear to exist." Blood advances vol. 1,14 (2017): 863-866. doi: https://doi.org/10.1182/bloodadvances.2017007369
Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13. PMID: 29296729; PMCID: PMC5737601.
Copy Download .nbib Format: NLM
Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure.

Blood advances

Attarian S, Yu C, Anderson KE, Friedman EW.
PMID: 29296735
Blood Adv. 2017 Jun 05;1(14):915-917. doi: 10.1182/bloodadvances.2017005660. eCollection 2017 Jun 13.

Hemin and hemodialysis had an additive effect in decreasing ALA and PBG in our patient with acute intermittent porphyria and renal failure.The time course of ALA and PBG reaccumulation after hemodialysis is not known.

Cite
Attarian S, Yu C, Anderson KE, et al. Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure. Blood Adv. 2017;1(14):915-917doi: 10.1182/bloodadvances.2017005660.
Attarian, S., Yu, C., Anderson, K. E., & Friedman, E. W. (2017). Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure. Blood advances, 1(14), 915-917. https://doi.org/10.1182/bloodadvances.2017005660
Attarian, Shirin, et al. "Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure." Blood advances vol. 1,14 (2017): 915-917. doi: https://doi.org/10.1182/bloodadvances.2017005660
Attarian S, Yu C, Anderson KE, Friedman EW. Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure. Blood Adv. 2017 Jun 05;1(14):915-917. doi: 10.1182/bloodadvances.2017005660. eCollection 2017 Jun 13. PMID: 29296735; PMCID: PMC5737596.
Copy Download .nbib Format: NLM
Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines.

Blood advances

Zhang Y, He L, Selimoglu-Buet D, Jego C, Morabito M, Willekens C, Diop MK, Gonin P, Lapierre V, Droin N, Solary E, Louache F.
PMID: 29296739
Blood Adv. 2017 Jun 13;1(14):972-979. doi: 10.1182/bloodadvances.2017004903. eCollection 2017 Jun 13.

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that typically associates with mutations in epigenetic, splicing, and signaling genes. Genetically modified mouse models only partially recapitulate the disease phenotype, whereas xenotransplantation of CMML cells in immunocompromised...

Cite
Zhang Y, He L, Selimoglu-Buet D, et al. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. Blood Adv. 2017;1(14):972-979doi: 10.1182/bloodadvances.2017004903.
Zhang, Y., He, L., Selimoglu-Buet, D., Jego, C., Morabito, M., Willekens, C., Diop, M. K., Gonin, P., Lapierre, V., Droin, N., Solary, E., & Louache, F. (2017). Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. Blood advances, 1(14), 972-979. https://doi.org/10.1182/bloodadvances.2017004903
Zhang, Yanyan, et al. "Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines." Blood advances vol. 1,14 (2017): 972-979. doi: https://doi.org/10.1182/bloodadvances.2017004903
Zhang Y, He L, Selimoglu-Buet D, Jego C, Morabito M, Willekens C, Diop MK, Gonin P, Lapierre V, Droin N, Solary E, Louache F. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. Blood Adv. 2017 Jun 13;1(14):972-979. doi: 10.1182/bloodadvances.2017004903. eCollection 2017 Jun 13. PMID: 29296739; PMCID: PMC5737594.
Copy Download .nbib Format: NLM
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.

Blood advances

Field JJ, Majerus E, Gordeuk VR, Gowhari M, Hoppe C, Heeney MM, Achebe M, George A, Chu H, Sheehan B, Puligandla M, Neuberg D, Lin G, Linden J, Nathan DG.
PMID: 29296811
Blood Adv. 2017 Aug 28;1(20):1645-1649. doi: 10.1182/bloodadvances.2017009613. eCollection 2017 Sep 12.

Adenosine A

Cite
Field JJ, Majerus E, Gordeuk VR, et al. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Adv. 2017;1(20):1645-1649doi: 10.1182/bloodadvances.2017009613.
Field, J. J., Majerus, E., Gordeuk, V. R., Gowhari, M., Hoppe, C., Heeney, M. M., Achebe, M., George, A., Chu, H., Sheehan, B., Puligandla, M., Neuberg, D., Lin, G., Linden, J., & Nathan, D. G. (2017). Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood advances, 1(20), 1645-1649. https://doi.org/10.1182/bloodadvances.2017009613
Field, Joshua J, et al. "Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease." Blood advances vol. 1,20 (2017): 1645-1649. doi: https://doi.org/10.1182/bloodadvances.2017009613
Field JJ, Majerus E, Gordeuk VR, Gowhari M, Hoppe C, Heeney MM, Achebe M, George A, Chu H, Sheehan B, Puligandla M, Neuberg D, Lin G, Linden J, Nathan DG. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Adv. 2017 Aug 28;1(20):1645-1649. doi: 10.1182/bloodadvances.2017009613. eCollection 2017 Sep 12. PMID: 29296811; PMCID: PMC5728341.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1080 entries